Reports Q4 revenue $282.648M, consensus $251.39M. “2024 was a pivotal year for Tandem, as we returned to strong sales growth both in and outside of the United States, while delivering industry-leading customer satisfaction,” said John Sheridan, president and chief executive officer. “We are continuing to transform our business in 2025 through the recent expansion of our U.S. sales force, commencing pharmacy coverage, and adding new features and indications to our robust portfolio as we work to improve the lives of people with diabetes.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Positioned for Growth with FDA Approval of Control IQ+
- FDA clears Tandem’s Control-IQ+ for type 2 diabetes treatment
- TNDM Upcoming Earnings Report: What to Expect?
- Tandem Diabetes price target raised to $44 from $42 at Bernstein
- Tandem Diabetes signs multi-year collaboration agreement with UVA